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F-Spondin Deficient Mice Have a High Bone Mass
Phenotype
Glyn D. Palmer1*.¤, Mukundan G. Attur1., Qing Yang1, James Liu1, Paxton Moon2, Frank Beier2,
Steven B. Abramson1
1 Division of Rheumatology, New York University School of Medicine and NYU Hospital for Joint Diseases, New York, New York, United States of America, 2 Department of
Physiology and Pharmacology, Schulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, Canada

Abstract
F-spondin is a pericellular matrix protein upregulated in developing growth plate cartilage and articular cartilage during
osteoarthritis. To address its function in bone and cartilage in vivo, we generated mice that were deficient for the F-spondin
gene, Spon1. Spon12/2 mice were viable and developed normally to adulthood with no major skeletal abnormalities. At 6
months, femurs and tibiae of Spon12/2 mice exhibited increased bone mass, evidenced by histological staining and micro
CT analyses, which persisted up to 12 months. In contrast, no major abnormalities were observed in articular cartilage at any
age group. Immunohistochemical staining of femurs and tibiae revealed increased levels of periostin, alkaline phosphate
and tartrate resistant acid phosphatase (TRAP) activity in the growth plate region of Spon12/2 mice, suggesting elevated
bone synthesis and turnover. However, there were no differences in serum levels of TRAP, the bone resorption marker, CTX1, or osteoclast differentiation potential between genotypes. Knockout mice also exhibited reduced levels of TGF-b1 in
serum and cultured costal chondrocytes relative to wild type. This was accompanied by increased levels of the BMPregulatory SMADs, P-SMAD1/5 in tibiae and chondrocytes. Our findings indicate a previously unrecognized role for Spon1 as
a negative regulator of bone mass. We speculate that Spon1 deletion leads to a local and systemic reduction of TGF-b levels
resulting in increased BMP signaling and increased bone deposition in adult mice.
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F-spondin TSR also operates as a functional TGF-b activation
domain. Treatment of human cartilage explant cultures with Fspondin was found to increase active TGF-b levels [8], while the
addition of the TSR domain to chick ciliary ganglion neuron
cultures has been shown to substitute the prosurvival effects of
TGF-b [10].
Beyond CNS regulation, several in vitro studies also implicate Fspondin in the regulation of musculoskeletal tissues. In periodontal
tissue, F-spondin localizes to mineralized cementum and has been
shown to promote osteoblast-like differentiation of periodontal
ligament cells into cementoblasts via induction of BMP-7 [6,12]. It
has also been shown to inhibit M-CSF induced cell migration and
differentiation of osteoclasts, in RAW 264 cell lines, suggesting an
additional anti-resorptive role in this tissue [13]. In articular
cartilage, we have previously reported induction of F-spondin
expression in human and rodent osteoarthritis [14]. In ex vivo
cultures of embryonic mouse tibiae, we showed inhibition of
longitudinal growth and altered growth plate morphology
following exogenous F-spondin addition, providing the strongest
indication yet, that F-spondin is involved in skeletal development
[7]. Despite these observations, the lack of gene knockout studies

Introduction
F-spondin (also known as SPON1 and VSGP) is a secreted,
heparin-binding extracellular matrix glycoprotein that belongs to
the thrombospondin (TSR) family. It is primarily associated with
the regulation of neuronal outgrowth in the embryonic central
nervous system [1–4]. More recently, F-spondin expression has
been found in non-neuronal tissues including ovary, lung [5],
periodontal tissue [6], embryonic growth plate cartilage [7] and
osteoarthritic cartilage [8]. Despite these observations, precise
physiological roles for F-spondin have yet to be elucidated.
In vitro studies have shown that F-spondin exhibits diverse cellregulatory functions. The C-terminal thrombospondin type 1
repeat (TSR) domain of the protein has been shown to mediate
many of its biological activities, including inhibition as well as
promotion of axonal outgrowth [2,4] regulation of amyloid
precursor protein cleavage [9], induction of PGE2 [8], ECM
binding [3] and cell survival [10]. The TSR domain also harbors
highly conserved motifs, KRFK and WxxW, which have been
shown to be required for thrombospondin mediated activation of
the latent TGF-b complex [11]. Early evidence suggests that the

PLOS ONE | www.plosone.org

1

May 2014 | Volume 9 | Issue 5 | e98388

Skeletal Phenotype of FS Null Mice

amplification, products were resolved on a 1% agarose gel and
visualized by ethidium bromide staining.

prevents a more definitive assessment of the role of F-spondin in
bone and cartilage physiology.
To address this further, the aim of the present study was to
identify the role of F-spondin in bone and cartilage development in
vivo, in mice that are null for the F-spondin gene, Spon1. Despite
our earlier findings, these mice undergo normal skeletal development, but show enhanced postnatal accumulation of trabecular
and cortical bone in the femur and tibia. These changes are
accompanied by abnormalities in components of the TGF-b
signaling pathway including TGF-b1 and SMADs. This report
represents the first indication for physiological control of bone
metabolism by F-spondin, possibly via disruption of latent TGF-b
activation.

Histological and immunohistochemical analyses
Whole embryo staining, dissection and paraffin embedding of
long bones, preparation of paraffin sections and safranin O/Fast
Green staining was performed as described [15]. Growth plate
measurements were performed by a blinded observer as before
[16].
For adult mice, knee joints were dissected from 6 month old
males and fixed for four days in 4% paraformaldehyde in PBS at
4uC. Specimens were decalcified in 10% EDTA in 0.05 M Tris
buffer at RT, until bones were soft and flexible (4–7 days at RT),
dehydrated in an ethanol series, cleared in xylene and embedded
in paraffin. Sections were cut to 5 mm and stained with Weigert’s
hematoxylin/Fast Green/Safranin-O for bone and cartilage.
Immunohistochemistry was performed at the histology core of
Hospital for Special Surgery, using antibodies for F-spondin
(rabbit polyclonal R4 antibody), alkaline phosphatase (Abcam),
and periostin (Sigma). All of these primary antibodies were
localized by the ABC avidin-streptavidin kit (Vector Laboratories)
resulting in a brown reaction product. All tissues were counterstained with hematoxylin. For TRAP staining sections were
reactivated in 0.2 M Tris buffer and incubated with TRAP
medium for 1–2 h at RT according to the method of Liu et al. [17]
and Barka and Anderson [18]. Sections were counterstained with
1% methyl green. Quantification of cartilage area and positive
immunostaining was performed using image J software (http://
rsbweb.nih.gov/). For each sample values represent an average of
a minimum of 4 stained sections of equivalent depth.

Materials and Methods
Generation of Spon12/2 mice and genotyping
Spon12/2 mice were generated in collaboration with the Texas
Institute of Genomic Medicine (TIGM) using a gene targeting
strategy that replaces the first coding exon of Spon1 with an IRES/
bGeo/PolyA cassette via homologous recombination. This
recombination removes the ATG start codon, preventing translation initiation. Mutant ES clones were generated and confirmed
by Southern blotting with 5’ and 39 flanking probes. Chimeric
mice were then generated by injection of ES cells into blastocysts
of C57BL/6 mice. Spon12/2 mice were obtained by crossing
heterozygous progeny of chimeric mice. Genotyping was performed using genomic DNA isolated from mouse tail biopsies
using allele-specific primers as follows: Primer 3, GACCGGAGATCTAGGAACCCCTAG, and primer 4, CACTCTCGCCAACAGCTGGAGCG, were designed from the first intron and
used to amplify the wild type allele, generating a 318-bp PCR
product; Primer 1, CTCCGCTCAGAGCAGCGCAGCTC, and
primer GT, CCCTAGGAATGCTCGTCAAGA, were designed
from the targeting vector and used to detect the mutant allele,
producing a 391-bp PCR product. The Spon1 targeting and
genotyping strategy are summarized in Figure 1A. For all analyses,
mice were euthanized by cervical dislocation following anesthesia
with xyaline and ketamine in accordance with the guidelines of the
Institutional Animal Care and Use Committee (IACUC) of New
York University.

Micro CT analyses
Mouse knees were studied by micro-computed tomography (mCT)
on Scanco mCT 35 (Scanco Medical, Bassersdorf, Switzerland)
system. Scans were performed in DPBS using 6 mm voxel size,
55KVp, 0.36 degrees rotation step (180 degrees angular range) and a
400 ms exposure per view. For trabecular bone, micro CT evaluation
was performed on a 1.2 mm region of metaphyseal spongiosa in the
proximal tibia and distal femur. The regions were located 100
microns above (femur) or below (tibia) the growth plate. For cortical
bone, measurements were performed on a 1.4 mm region of the middiaphysis of the femur. The Scanco mCT software (HP, DECwindows Motif 1.6) was used for 3D reconstruction and viewing of
images. After 3D reconstruction, volumes were segmented using a
threshold of 0.4 g/c for trabecular and 0.6 g/cc for cortical bone.
Tissue mineral density (TMD) and directly measured bone volume
fraction (BV/TV), surface to volume ratio (BS/BV), thickness
(Tb.Th), number (Tb.N) and separation (Tb.Sp) were calculated for
the trabecular bone. Cortical bone measurements included total area
(TA), bone area (BA), porosity, and thickness of the cortex (CtTh).
Only male mice (WT and KO) were included for mCT analyses.

Ethics Statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. All
procedures performed in the study were approved by the
Institutional Animal Care and Use Committee (IACUC) of New
York University School of Medicine under protocol number
121006-01.

RT-PCR analysis
Tissues (brain, bone, lung, liver) were harvested from 6 month
old male mice or 5 day old littermates (rib cartilage) and
homogenized using a tissue grinder. For bone, whole tissue
including matrix, bone marrow and periosteum was processed for
RNA extraction. Total RNA was extracted using Trizol reagent
and RNA was purified using an RNeasy micro kit (Qiagen)
according to the RNeasy cleanup protocol. cDNA was synthesized
from 1 mg of RNA using MMLV reverse transcriptase and
Oligo(dT)18 as primers (Clontech). PCR was performed using
Spon1 specific primers AGAGGCACCGTATGGTCAAG (forward) and GACCACTCGCTGAGTTCACA (reverse). Gapdh
(Clontech, #ST0253) was used as a housekeeping control. After
PLOS ONE | www.plosone.org

Serum Biomarker Assays
Serum samples were collected from 6 and 12 month old WT
and KO mice and assayed for the bone degradation markers,
CTX-1, and TRAP (TRACP 5b) using commercially available
ELISA kits (Immune Diagnostic System Inc Fountain Hill, AZ).

Cell culture
Chondrocytes were isolated from intact rib cages harvested
from 5 d old littermates according to the method of Gosset M et al.
[19]. Cells were cultured to confluence (4–5 days after harvest) in
DMEM with 10% FBS. Upon confluence, the media was changed
2
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Fig. 1. Targeting strategy for generation of Spon12/2 mice. (A) The murine Spon1 gene was disrupted by homologous recombination to
replace exon 1 (represented by grey box) with an IRES/bGeo/PolyA cassette. Numbered arrows (red) indicate PCR primers used for genotyping of WT
and mutant loci. (B) Identification of Spon1 mutant mice by PCR. Wild type (WT) mice were distinguished by PCR products from primer set 3 + 4, null
mice (2/2) were positive for 1 + GT, and heterozygous mice (+/2) were positive for both. (C) RT-PCR analysis of Spon1 expression in selected tissues.
Gapdh amplification was performed as a housekeeping control.
doi:10.1371/journal.pone.0098388.g001

and ascorbate 2-phosphate (50 mg/ml) and b-glycerolphosphate
(10 mM) were added to initate hypertrophic differentiation. After
48 h, media was collected for measurement of TGF-b levels, and
cells were lysed for detection of phosphorylated SMADs.

tants and assayed for luciferase activity using the Luciferase reporter
assay system (Promega). Luminescence was measured using a Tristar
LB 941 luminometer (Berthold Technologies).

Detection of SMADs
Osteoclast Differentiation

Proteins were extracted from bone tissue specimens and
chondrocytes by incubation with RIPA lysis buffer (Santa Cruz)
for 30 min at 4uC. After centrifugation, proteins were quantified
using BCA reagent and 50 mg of cell lysates were electrophoresed
on a 10% SDS-PAGE gel. Proteins were transferred to polyvinylidene difluoride membranes (Millipore Corporation) and
blots were probed with monoclonal antibodies against phosphorylated and non-phosphorylated SMADs from the Phospho-SMAD
Antibody Sampler Kit (Cell Signaling Technologies). b-tubulin
was used as loading control. Horseradish peroxidase-coupled
secondary antibodies were used for detection (Jackson Immuno
Research Laboratories) and blots were developed using the
enhanced chemiluminescence Western blot system (Pierce) on a
Kodak automated developer. Semi-quantitative measurements of
SMAD levels were performed by denistometric analysis of
immunoblots using image J software.

Bone marrow was flushed from cut femurs and tibiae with a
syringe containing aMEM supplemented with 10% FCS and
plated overnight. Non-adherent cells were collected the following
day and purified by Ficoll gradient centrifugation. Collected cells
were washed and resuspended in osteoclast induction medium
(aMEM containing 10% FCS, 40 ng/ml M-CSF and 60 ng/ml
RANKL). Control cultures (day 0) contained media without
cytokine supplementation. After 6 days, cells were fixed with
citrate solution and stained for TRAP using the Acid Phosphatase,
Leukocyte (TRAP) Kit and protocol (Sigma). For quantitative gene
expression analysis, RNA was extracted at various time points,
reverse transcribed and real-time PCR reactions were performed
with SYBR green PCR reagents using the ABI Prism 7300
sequence detection system (Applied Biosystems).

Measurement of TGF-b levels
Statistics

To determine TGF-b levels in recovered tissues of wild type and
Spon12/2 mice, specimens were lysed in RIPA lysis buffer. Total
TGF-b1 levels were then measured by ELISA (R&D systems)
following acidification of samples by treatment with 0.2 M HCl
according to the manufacturer’s protocol. TGF-b1 levels were
normalized to total protein content for each sample, determined
using the BCA protein assay kit (Pierce). In costal chondrocyte
cultures, total TGF-b1 levels were measured by ELISA following
acidification of cell culture supernatants. For accurate quantification
of active TGF-b levels, we employed a cell-based reporter assay as
previously described [8]. Briefly, mink lung epithelial cells (MLEC),
stably transfected with a TGF-b responsive luciferase reporter gene,
were incubated overnight with chondrocyte culture media supernaPLOS ONE | www.plosone.org

Results are expressed as mean 6 SEM. For mCT, TGF-b and
SMAD measurements, statistical differences between groups were
assessed by students t test. P,0.05 was taken as minimum
significance level.

Results
Spon12/2 mice are viable and show histological evidence
of increased bone
F-spondin (Spon12/2) null mice were generated using a
targeting strategy that removes the first exon of Spon1 (Fig 1A),
and genotyped using mutant and allele-specific primers (Fig 1B).
3
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Spon12/2 mice have increased levels of bone markers

All mice were viable and born at the expected Mendelian ratio of
1:2:1 (wild type:heterozygous:null). Initial macroscopic observation
at birth and in mice aged 1-12 months revealed no gross
anatomical differences or significant changes in body weight
between wild type, heterozygous, and null mice. In wild type mice
(WT), RT-PCR revealed expression of F-spondin mRNA in brain,
lung, bone, liver and hypertrophic cartilage from rib, consistent
with our previous observations (Fig 1C) [7]. Among isolated cell
cultures of growth plate chondrocytes, calvaria osteoblasts, and in
vitro differentiated osteoclasts, Spon1 expression was detected only
in chondrocytes (data not shown), in agreement with our previous
analysis of chick and mouse cartilage [7]. Importantly, no Spon1
PCR products were detected in any tissues or cell cultures isolated
from knockout (KO) mice (Fig 1C).
Since Spon1 expression has previously been demonstrated in
embryonic growth plate chondrocytes and osteoarthritic cartilage,
we first examined neonatal and adult mice for evidence of skeletal
malformations and possible cartilage/bone phenotypes. Whole
body skeletal staining of newborn mice by Alizan Red (bone) and
Alcian Blue (cartilage) demonstrated no abnormalities in skeletal
size or morphology between genotypes (Fig 2A). Histological
analyses of sections of long bones from WT and Spon12/2 mice at
birth also revealed no differences in bone length, ossification
patterns or hypertrophic zone length in the growth plate (Fig 2A).
Thus despite its reported expression in embryonic cartilage, Spon1
deletion did not appear to impair growth plate maturation or
skeletal formation. In contrast, histological analysis of mouse joints
at 6 months suggests involvement of Spon1 in the regulation of
bone. (Fig 2B). Safranin-O/Fast Green staining revealed a marked
increase in trabecular bone staining in Spon12/2 mice in the
medullary cavity and epiphyseal region below the articular
cartilage (arrows, Fig 2B), while the areas of articular and growth
plate cartilage were similar between genotypes (graph, Fig 2B).
These observations suggest a bone, but not cartilage phenotype in
Spon12/2 mice.

We next determined whether the differences in bone architecture were accompanied by correlative changes in markers of bone
formation and resorption. To address this we performed
immunostaining of 6 month old tibiae for markers associated with
bone turnover. Staining of 6 month old tibiae with anti-F-spondin
antibody revealed positive cell- and matrix-associated staining in
epiphyseal cartilage of WT mice (Fig 4). The corresponding region
in Spon12/2 mice was negative for F-spondin staining, but
revealed greater levels of bone markers associated with increased
synthesis and turnover. Along the growth plate and adjacent
trabecular bone of KO mice, the relative area of positive
immunostaining was 1.5-fold higher for alkaline phosphatase
and periostin compared to WT (Fig 4). Somewhat contradictory to
the high bone mass phenotype, this region also had increased
numbers of TRAP positive cells, mostly concentrated at the
junction of the epiphyseal growth plate and bone marrow cavity
(Fig 4). The same pattern was observed in the femurs (not shown).
Together these findings indicate that the absence of Spon1 in
epiphsyeal cartilage associates with increased levels of bone
synthesis and resorption markers in the growth plate and adjacent
trabecular bone.

Spon1 deletion does not affect serum biomarker levels or
osteoclast differentiation
The elevated TRAP staining in mouse tibiae of Spon12/2 mice
was surprising given that the mice exhibit an increased bone mass
phenotype. Therefore, we examined serum markers of bone
resorption for further evidence of enhanced bone turnover in
Spon12/2 mice. Serum levels of TRAP and CTX-1 - a C-terminal
telopeptide of type I collagen, were measured in 6 and 12 month
old WT and KO mice. Levels of both markers did not significantly
change in KO mice relative to WT for either age group indicating
that overall resorption is in fact similar between genotypes (Fig 5A).
We next determined whether F-spondin deletion in bone
marrow progenitor cells leads to an enhanced ability for osteoclast
maturation and could thus account for increased TRAP staining in
Spon12/2 tibiae. Bone marrow was harvested from 6 month old
WT and Spon12/2 littermates and non-adherent fraction was
subjected to M-CSF and RANKL induced differentiation, ex vivo.
After 6 days of induction, numbers of TRAP positive osteoclasts
were counted and compared between genotypes. No differences
were observed in osteoclast number between WT and KO mice
(Fig 5B). Similarly, expression of mRNAs for osteoclast marker
genes, acid phosphatase-5, cathepsin K, calcitonin receptor and
MMP9 did not significantly change in KO mice (Fig 5C). Thus,
despite the high bone mass condition indicated by micro-CT, and
a localized increase of TRAP positive cells along the growth plate,
no further indication of abnormalities in bone turnover or
osteoclast activity were noted in response to Spon1 deletion.

Spon12/2 mice shave increased trabecular and cortical
bone by micro-CT
To establish whether increased trabecular staining reflects a
high bone mass condition in Spon12/2 mice, we performed
quantitative analyses of bone structure using micro-CT on femurs
and tibiae from mice aged 3, 6 and 12 months. Relative to WT,
femurs and tibiae from Spon12/2 mice exhibited a marked
increase in trabecular bone (Fig 3A). At 6 months, this phenotype
was most pronounced, evidenced by a ,60% higher bone volume
(Fig 3A; P,0.001). This was accompanied by increased femur and
tibia trabecular number (26 and 40% respectively; P,0.0005) and
decreased trabecular spacing (Tb.Sp) (18 and 26%; P,0.01). In
contrast, there were no differences in either trabecular thickness
(Tb.Th) or total mineral density (TMD). Increased trabecular
bone was still apparent at 12 months, however only Tb.Sp
remained statistically significant (P,0.05). Micro-CT measurements of cortical bone revealed a trend of increased cortical area
and decreased porosity at both 6 and 12 months in Spon12/2 mice;
however these differences were not significant (Fig 3B). Spon12/2
mice also had increased femurs cortical thickness (,16%, P,0.01)
relative to WT mice at 6 months, but this was not evident at 12
months (Fig 3B). Interestingly, 3D micro-CT images revealed that
the endocortical perimeter of Spon12/2 femurs appeared distinctly
irregular at both 6 and 12 months, suggesting abnormalities in
bone remodeling (arrows, Fig 3B). Together the data indicate a
high bone mass phenotype in femurs and tibiae of Spon12/2 mice;
the phenotype appears to be age-dependent and most pronounced
at 6 months of age.
PLOS ONE | www.plosone.org

Spon12/2 mice have reduced levels of serum and
chondrocyte-derived TGF-b
TGF-b is known to regulate multiple aspects of bone synthesis
and resorption [20]. Our previous studies have demonstrated that
F-spondin has the capacity to act as a latent TGF-b1 activating
protein [8], therefore we next examined Spon12/2 mice for TGFb1 levels, to determine whether the high bone mass condition in
KO mice associates with abnormal TGF-b signaling. In serum,
which contains a large pool of latent TGF-b1, total TGF-b1 levels
were ,50% lower in KO mice relative to WT (Fig 6A; P,0.05).
However, among tissues that were positive for Spon1 expression in
WT mice by RT-PCR (see Fig 1B), brain, bone, lung and liver did
4
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Fig. 2. Spon12/2 mice exhibit post-natal accumulation of bone. (A) WT and Spon12/2 skeletons were prepared from newborn (P0) littermates
and stained with Alizarin Red/Alcian Blue to assess skeletal size and ossification. Right Panel P0 Tibiae were stained with H&E and the areas
corresponding to the hypertrophic zone (HZ) and total growth plate (TGP) measured. Graph shows similar average HZ lengths in Spon12/2 and WT
from 6 littermate pairs. (B) Safranin O/Fast Green staining of tibia and femur from 6 month old male mice. Panels below show Safranin-O/Fast Green
staining articular cartilage from the medial tibial plateau of 6 month old male mice. Arrows denote areas of increased bone deposition in Spon12/2
mice. Graph indicates mean area of tibial articular cartilage (AC) and growth plate cartilage (GP) for 5 WT and KO mice; differences were not
significant (P$0.2). Scale bars; 200 mm for knee sections and 100 mm for articular cartilage.
doi:10.1371/journal.pone.0098388.g002

TGF-b relative to WT (Fig 6C). In KO mice, total and active
levels were significantly reduced by 50% and 23% respectively
(P,0.05, Fig 6C). In heterozygous mice, TGF-b levels were
intermediate between WT and KO. As expected, TGF-b levels
correlated with Spon1 mRNA levels for each genotype, indicating a
dose-dependent effect (Fig 6C). Altogether, these findings provide
evidence that serum and chondrocyte-derived TGF-b are regulated by Spon1 in vivo. Moreover, chondrocyte-mediated regulation
of TGF-b by Spon1 suggests a possible direct link between Fspondin expression in epiphyseal cartilage of femurs and tibiae and
the regulation of bone mass.

not have significantly lower TGF-b1 levels following Spon1 deletion
(Fig 6B).
To examine more closely a direct link between Spon1 deletion
and TGF-b activation, we measured cell-derived TGF-b levels in
Spon12/2 and WT mice. For this study we used hypertrophic
chondrocytes since our expression data indicated high levels
endogenous F-spondin in rib (Fig 1) and tibial cartilage (Fig 4) by
qPCR and immunostaining, respectively. Moreover, in isolated
cell cultures mRNA levels of F-spondin were detected in
hypertrophic chondrocytes, but not osteoblasts or osteoclasts (data
not shown). Levels of secreted, total and active TGF-b were
examined in cell cultures of rib chondrocytes isolated from 5 d old
mice (Fig 6C). In culture, these cells are known to exhibit a
hypertrophic phenotype, and mimic the cellular processes of
terminal differentiation observed during growth plate maturation
of long bones. For these studies, Spon1+/2 heterozygous mice were
included as an additional group to determine whether Spon1mediated TGF-b effects were gene-dose dependent. Cultures from
both heterozygous and KO mice secreted less total and active

PLOS ONE | www.plosone.org

P-SMAD levels are altered in Spon12/2 mice
As further evidence of altered TGF-b canonical pathway
signaling, we investigated levels of receptor regulated SMADs in
WT and Spon12/2 mice. In both osteoblasts and maturing
chondrocytes, SMAD2/3 activation is associated with TGF-b
signaling, while SMAD1/5/8 is associated with BMP [21–24].
Western blot of protein extracts isolated from tibiae of 6 month old

5

May 2014 | Volume 9 | Issue 5 | e98388

Skeletal Phenotype of FS Null Mice

Fig. 3. Spon12/2 mice have increased trabecular and cortical bone. (A) Representative 3D mCT images showing regions of trabecular bone in
the distal femur (F) and proximal tibia (T). Graphs represent measurements of total body weight (g), trabecular bone volume (bone volume per tissue
volume, BV/TV), trabecular number (Tb.N/mm) and trabecular spacing (Tb.sp/mm) in the femurs and tibiae of 3 month (n = 4), 6 month (n = 10–11)
and 12 month (n = 6) -old Spon12/2 and WT mice. (B) Representative 3D mCT images showing regions of femoral cortical bone in WT and Spon12/2
mice. Graph represents measurement of total area (Tt.Ar mm2), cortical area (Ct.Ar mm2, cortical thickness (Ct.Th/mm) and intracortical porosity (%) of
6 month (n = 6–11) and 12 month (n = 5) mice. Arrows show the irregular surfaces along the endosteal perimeters of Spon12/2 mice. Statistically
significant differences from WT mice groups are indicated by *(P,0.05).
doi:10.1371/journal.pone.0098388.g003

mice revealed that Spon12/2 mice showed a 7-fold increase in
levels of Phosphorylated-SMAD1/5 (P-SMAD1/5) compared to
WT (P,0.005; Fig 7A). In contrast, levels of P-SMAD2 and PSMAD3 in KO mice were increased only marginally above WT
controls (Fig 7A). To examine if Spon1 deletion similarly affects PSMAD levels in maturing chondrocytes, Western blot was also
PLOS ONE | www.plosone.org

performed on extracts from parallel rib chondrocyte cultures from
Fig 6B. Relative to WT, P-SMAD1/5 levels increased slightly in
chondrocytes from heterozygous mice, and increased considerably
in chondrocytes from KO mice (Fig 7B). In contrast, P-SMAD2
and P-SMAD3 levels were either unchanged or slightly lower after
normalization (Fig 7B).
6
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Fig. 4. Spon12/2 mice tibiae exhibit increased staining of markers of bone synthesis and turnover. Immunohistochemical staining of
mid-saggital sections of tibia from 6 month old WT and Spon12/2 mice with antibodies for F-spondin (SPON1), Alkaline Phosphatase (ALPL), Periostin
(POSTN), and tartrate resistant acid phosphatase (TRAP) as a marker of osteoclast activity. Sections were counterstained with either 1% methyl green
(TRAP) or hematoxylin. Arrrows indicate areas of increased staining in the epiphyseal cartilage and adjacent trabecular bone of Spon12/2 tibiae.
Adjacent graphs correspond to quantification of positive stained area (SPON1, ALP, POSTN) and osteoclast number per field (TRAP). Quantification
was performed on 4 sections per specimen, and values represent the average of 4 mice per genotype. * = P,0.05. Scale bars; 200 mm for antibody
stainings and 100 mm for TRAP staining.
doi:10.1371/journal.pone.0098388.g004

was observed as positive immunostaining in the epiphyseal
cartilage region of long bones. We speculate that its inactivation
primarily affects chondrocytes within this region, resulting in
decreased secretion of TGF-b, which in turn leads to reduced
TGF-b signaling in adjacent bone, and enhanced activation of
SMAD 1/5 dependent osteogenic pathways.
Somewhat surprisingly, Spon1 deletion did not cause any gross
abnormalities in growth plate organization or significant impairment of endochondral development. This finding was unexpected
given that we have previously shown F-spondin expression in
hypertrophic cartilage and its regulation of chondrocyte terminal
differentiation when added exogenously to cell and tibia explant
cultures [7]. Moreover, chondrocyte cell cultures also exhibited
reduced TGF-b levels and elevation of P-SMAD1/5, both of

These findings show that Spon1 KO mice have decreased TGFb1 levels and enhanced activation of SMAD1/5 at both the tissue
and chondrocyte level. The reduction in TGF-b1 levels may
represent a shift towards BMP signaling in bone and hypertrophic
cartilage, culminating in a high bone mass phenotype.

Discussion
Our findings indicate that Spon1 gene inactivation leads to
increased bone in adult murine femurs and tibiae. This represents
the first indication of the involvement of Spon1 in the regulation of
bone metabolism. Bone changes were accompanied with a
reduction in serum and chondrocyte-derived TGF-b levels and
increased levels of P-SMAD1/5. In WT mice, Spon1 expression
PLOS ONE | www.plosone.org
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Fig. 5. Biomarkers of bone resorption and osteoclast differentiation potential are not affected by Spon12/2 deletion. (A) Serum levels
of TRAP and CTX-1 in 6 month (n = 12) and 12 month (n = 6) old male mice. (B) In vitro osteoclast differentiation of non-adherent bone marrow cells
isolated from male WT and KO littermates. Images show TRAP positive osteoclasts 6 days after stimulation with RANKL and MCSF. Cell numbers
represent average counts from 5 separate fields using a 20x objective (n = 4). Only positively stained cells with .3 nuclei were counted. (C) Relative
mRNA levels, determined by RT-qPCR of osteoclast marker genes, following induction of differentiation (n = 4). Data represent mean values from 4
littermate pairs.
doi:10.1371/journal.pone.0098388.g005

relevance to these findings, Glatt et al. demonstrated that C57Bl/6
mice undergo trabecular bone loss that is characterized by a rapid
decline between 2 and 6 months and a more gradual decrease
thereafter, while cortical bone remains relatively stable [28].
Consistent with these data, progressive bone loss was also evident
in WT mice from our study which were analyzed within a similar
time frame (3–12 months). Thus the variations among different
age groups could reflect the impact of underlying bone loss and
remodeling processes masking the Spon12/2 phenotype. Further
analysis of aged mice would be needed to determine if Spon12/2
inactivation continues to slow age-related bone loss after 12
months.
Despite the high bone mass phenotype of adult Spon12/2 mice
there have been no previous reports of F-spondin expression in
adult bone, or isolated cell cultures of osteoblasts or osteoclasts.
Likewise, we found either low or absent endogenous F-spondin
levels in osteoclasts and osteoblasts of WT mice by QPCR. Gene
expression profiling has identified significant upregulation of Fspondin in bone marrow cells of rats, following induction of
osteoporosis [29]. This finding suggests an association of F-spondin

which have been shown to affect terminal differentiation [25]. The
lack of pronounced defects in endochondral development may be
attributed to compensatory effects by other TSP family members
following Spon1 deletion. In this regard, Spon12/2 mice share
similarities in skeletal phenotype with Tsp2 and Tsp3 null mutants
in that prenatal development appears normal, but mice exhibit
bone accumulation during adulthood [26,27]. For articular
cartilage development and maintenance, our findings suggest that
Spon1 is also dispensable, evidenced by ‘normal’ cartilage thickness
and morphology in KO mice up to 12 months of age. This finding
was not surprising, as we have previously shown that Spon1 is not
expressed in normal articular cartilage, and present only after
onset of osteoarthritis [14].
Analysis of femurs and tibiae by micro-CT revealed that the
increased bone mass associated with Spon1 deletion in adult mice
varied with age. Bone volume (BV/TV) and trabecular number
(Tb.N) increased in null mice at 3 months, but these differences
were not significant until 6 months of age. By 12 months, the
phenotype was still apparent in trabecular bone, but to a lesser
degree, and no changes were observed in cortical bone. Of
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Fig. 6. TGF-b1 levels are reduced in serum and chondrocytes of Spon12/2 mice. Total (latent + active) TGF-b1 levels in protein extracts
isolated from (A) serum (n = 14-16) or (B) indicated organs (n = 4–5) of 6 month old WT and Spon12/2 mice. TGF-b1 was measured by ELISA. (C) Total
and active TGF-b levels in conditioned media of rib chondrocyte cultures (n = 4) isolated from costal cartilage of 5 day old WT, HET and KO littermates.
Total TGF-b levels were determined by ELISA, active TGF-b levels were measured using MLEC bioassays. Corresponding Spon1 mRNA levels,
determined by QPCR, are shown for each group (WT = 100%). Statistically significant differences in total TGF-b level to WT group are indicated by
*(P,0.05). Statistically significant difference in active TGF-b level to WT group is indicated by # (P,0.05).
doi:10.1371/journal.pone.0098388.g006

regulation of a TGF-b autocrine loop, or inhibition of TGF-b
synthesis levels via an alternate pathway. TGF-b levels were also
significantly reduced in serum of KO mice, but not in other tissues
that also showed endogenous expression of F-spondin mRNA in
WT animals. These observations may reflect tissue specific
variations in TGF-b regulatory proteins that promote its synthesis
and activation. Further genetic approaches will be needed to
clarify the role of serum and chondrocyte-derived TGF-b in Spon1
regulation of bone metabolism.
Genetic deletion of TGF-b-binding ECM proteins LTBP-3,
fibrillin-1, fibrillin-2, have also led to bone phenotypes in KO mice
[30,31]. In both cases, the authors speculate that defects in
extracellular matrix assembly directly affect TGF-b bioavailability
and subsequent regulation of bone mass. By comparing fibrillin-1
and fibrillin-2 mutant mice, Nistala et al. showed that reduced
bone mass and impaired osteoblast maturation occur in response
to elevated TGF-b when P-SMAD2/3 levels are increased relative
to P-SMAD1/5 [31]. Our findings are similar in that Spon12/2
mice display the opposing trend; increased bone, decreased TGFb and increased levels of P-SMAD1/5. Collectively, these
observations suggest an inverse relationship between TGF-b levels
and bone synthesis in vivo, via the differential activation of SMAD
family transcription factors. Increased SMAD1/5 levels are
compatible with increased bone mass, since both of these
molecules have been shown to co-operate with RUNX-2 in
promoting BMP-driven osteoblast differentiation [32]. Moreover,

with bone loss; however its role was not investigated further. While
the mechanism underlying the increased bone phenotype was not
directly determined in our study, we did not find any evidence of
impaired bone resorption or osteoclast maturation in Spon12/2
mice, despite a localized increase in TRAP staining in femurs and
tibia. A potential explanation for this discrepancy is that serum
levels represent all bone, and osteoclast differentiation assays were
determined from bone marrow extracts obtained from multiple
locations. The increased TRAP staining, along with alkaline
phosphatase and periostin may therefore reflect a localized
increase in overall bone turnover within the growth plate region.
A limitation of our study is that analyses were confined to femurs
and tibiae only: therefore it is not known whether the bone
phenotype also extends to vertebrae or intramembranous bones.
Since TGF-b regulates both synthetic and resorptive processes
of bone development and homeostasis [20], extracellular matrix
proteins that either, bind, activate or sequester the latent TGF-b
complex are also likely to play an important role in regulating
bone remodeling. We have previously reported that F-spondin
increases active TGF-b1 levels in OA and hypertrophic cartilage
[7,8]. The current study showed further evidence of TGF-b
regulation by Spon1 and provides a possible mechanism for
regulation of bone mass. In agreement with our previous in vitro
observations, active TGF-b levels were reduced in cultured rib
chondrocytes of KO mice. Somewhat unexpectedly, total (latent +
active) TGF-b1 levels were also reduced, suggesting either down-
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Fig. 7. Spon12/2 mice have increased levels of P-SMAD1/5. (A) Western blot showing levels of SMAD and P-SMAD in protein extracts from
whole tibia of 6 month old WT and Spon12/2 mice. Histograms represent densitometric analyses of SMAD blots. Statistically significant difference to
WT group is indicated by *(P,0.001). (B) Western blot showing levels of P-SMAD in protein extracts from cultured costal chondrocytes isolated from 5
d old WT and Spon12/2 mouse rib cartilage. a-tubulin was used as a loading control. Blot is representative of chondrocytes isolated from 3 littermate
pairs.
doi:10.1371/journal.pone.0098388.g007
micro-CT and histology. We also thank Dr. Shoshana Yakar (Dept. of
Basic Science and Craniofacial Biology, New York University College of
Dentistry, New York 10010) for her critique and assistance with osteoclast
differentiation assays.

TGF-b has been shown to impair BMP-associated SMAD1/5/8
signaling and osteoblast differentiation in vitro [33,34]. Thus,
increased SMAD 1/5 signaling following a reduction in local or
systemic TGF-b levels may offer a plausible mechanism for
increased bone mass in Spon1 null mice.

Author Contributions

Acknowledgments

Conceived and designed the experiments: GDP MGA QY FB SBA.
Performed the experiments: GDP MGA QY JL PM. Analyzed the data:
GDP MGA FB SBA. Contributed reagents/materials/analysis tools: GDP
MGA FB. Wrote the paper: GDP MGA.

Funding for this project was provided by National Institute of Health grant
AR054817 (SBA). We thank Dr. Stephen Doty and Lyudmila Lukashova
(Hospital for Special Surgery, New York 10021) for their assistance with

References
3. Feinstein Y, Borrell V, Garcia C, Burstyn-Cohen T, Tzarfaty V, et al. (1999) Fspondin and mindin: two structurally and functionally related genes expressed in
the hippocampus that promote outgrowth of embryonic hippocampal neurons.
Development 126(16):3637–48.
4. Tzarfati-Majar V, Burstyn-Cohen T, Klar A (2001) F-spondin is a contactrepellent molecule for embryonic motor neurons. Proc Natl Acad Sci U S A
98(8):4722–7.

1. Klar A, Baldassare M, Jessell TM (1992) F-spondin: a gene expressed at high
levels in the floor plate encodes a secreted protein that promotes neural cell
adhesion and neurite extension. Cell 69(1):95–110.
2. Burstyn-Cohen T, Tzarfaty V, Frumkin A, Feinstein Y, Stoeckli E, et al. (1999)
F-Spondin is required for accurate pathfinding of commissural axons at the floor
plate. Neuron 23(2):233–46.

PLOS ONE | www.plosone.org

10

May 2014 | Volume 9 | Issue 5 | e98388

Skeletal Phenotype of FS Null Mice

5. Miyamoto K, Morishita Y, Yamazaki M, Minamino N, Kangawa K, et al.
(2001) Isolation and characterization of vascular smooth muscle cell growth
promoting factor from bovine ovarian follicular fluid and its cDNA cloning from
bovine and human ovary. Arch Biochem Biophys 390(1):93–100.
6. Kitagawa M, Ao M, Miyauchi M, Abiko Y, Takata T (2012) F-spondin regulates
the differentiation of human cementoblast-like (HCEM) cells via BMP7
expression. Biochem Biophys Res Commun 418(2):229–33.
7. Palmer GD, Piton AH, Thant LM, Oliveira SM, D’Angelo M, et al. (2010) Fspondin regulates chondrocyte terminal differentiation and endochondral bone
formation. J Orthop Res 28(10):1323–9.
8. Attur MG, Palmer GD, Al-Mussawir HE, Dave M, Teixeira CC, et al. (2009) Fspondin, a neuroregulatory protein, is up-regulated in osteoarthritis and
regulates cartilage metabolism via TGF-beta activation. Faseb J 23(1):79–89.
9. Hoe HS, Wessner D, Beffert U, Becker AG, Matsuoka Y, et al. (2005) F-spondin
interaction with the apolipoprotein E receptor ApoEr2 affects processing of
amyloid precursor protein. Mol Cell Biol 25(21):9259–68.
10. Peterziel H, Sackmann T, Strelau J, Kuhn PH, Lichtenthaler SF, et al. (2011) Fspondin regulates neuronal survival through activation of disabled-1 in the
chicken ciliary ganglion. Mol Cell Neurosci 46(2):483–97.
11. Ribeiro SM, Poczatek M, Schultz-Cherry S, Villain M, Murphy-Ullrich JE
(1999) The activation sequence of thrombospondin-1 interacts with the latencyassociated peptide to regulate activation of latent transforming growth factorbeta. J Biol Chem 274(19):13586–93.
12. Kitagawa M, Kudo Y, Iizuka S, Ogawa I, Abiko Y, et al. (2006) Effect of Fspondin on cementoblastic differentiation of human periodontal ligament cells.
Biochem Biophys Res Commun 349(3):1050–6.
13. Oka H, Mori M, Kihara H (2011) F-spondin inhibits migration and
differentiation of osteoclastic precursors. J Periodontol 82(12):1776–83.
14. Appleton CT, Pitelka V, Henry J, Beier F (2007) Global analyses of gene
expression in early experimental osteoarthritis. Arthritis Rheum 56(6):1854–68.
15. Wang G, Woods A, Agoston H, Ulici V, Glogauer M, et al. (2007) Genetic
ablation of Rac1 in cartilage results in chondrodysplasia. Dev Biol 306(2):612–
23.
16. Ulici V, Hoenselaar KD, Agoston H, McErlain DD, Umoh J, et al. (2009) The
role of Akt1 in terminal stages of endochondral bone formation: angiogenesis
and ossification. Bone 45(6):1133–45.
17. Liu CC, Sherrard DJ, Maloney NA, Howard GA (1987) Reactivation of
inhibited bone acid phosphatase and its significance in bone histomorphometry.
J Histochem Cytochem 35(12):1355–63.
18. Barka T, Anderson PJ (1962) Histochemical Methods for Acid Phosphatase
using Hexazonium Pararosanilin as couplet. J. Histochem.Cytochem 10:741–47.
19. Gosset M, Berenbaum F, Thirion S, Jacques C (2008) Primary culture and
phenotyping of murine chondrocytes. Nat Protoc 3(8):1253–60.
20. Janssens K, ten Dijke P, Janssens S, Van Hul W (2005) Transforming growth
factor-beta1 to the bone. Endocr Rev 26(6):743–74.

PLOS ONE | www.plosone.org

21. Zuscik MJ, Baden JF, Wu Q, Sheu TJ, Schwarz EM, et al. (2004) 5-azacytidine
alters TGF-beta and BMP signaling and induces maturation in articular
chondrocytes. J Cell Biochem 92(2):316–31.
22. Ferguson CM, Schwarz EM, Reynolds PR, Puzas JE, Rosier RN, et al. (2000)
Smad2 and 3 mediate transforming growth factor-beta1-induced inhibition of
chondrocyte maturation. Endocrinology 141(12):4728–35.
23. Kawamura I, Maeda S, Imamura K, Setoguchi T, Yokouchi M, et al. (2012)
SnoN suppresses maturation of chondrocytes by mediating signal cross-talk
between transforming growth factor-beta and bone morphogenetic protein
pathways. J Biol Chem 287(34):29101–13.
24. Shi Y, Massague J (2003) Mechanisms of TGF-beta signaling from cell
membrane to the nucleus. Cell 113(6):685–700.
25. van der Kraan PM, Blaney Davidson EN, Blom A, van den Berg WB (2009)
TGF-beta signaling in chondrocyte terminal differentiation and osteoarthritis:
modulation and integration of signaling pathways through receptor-Smads.
Osteoarthritis Cartilage 17(12):1539–45.
26. Delany AM, Hankenson KD (2009) Thrombospondin-2 and SPARC/
osteonectin are critical regulators of bone remodeling. J Cell Commun Signal
3(3–4):227–38.
27. Hankenson KD, Hormuzdi SG, Meganck JA, Bornstein P (2005) Mice with a
disruption of the thrombospondin 3 gene differ in geometric and biomechanical
properties of bone and have accelerated development of the femursl head. Mol
Cell Biol 25(13):5599–606.
28. Glatt V, Canalis E, Stadmeyer L, Bouxsein ML (2007) Age-related changes in
trabecular architecture differ in female and male C57BL/6J mice. J Bone Miner
Res 22(8):1197–207.
29. Xiao Y, Fu H, Prasadam I, Yang YC, Hollinger JO (2007) Gene expression
profiling of bone marrow stromal cells from juvenile, adult, aged and
osteoporotic rats: with an emphasis on osteoporosis. Bone 40(3):700–15.
30. Dabovic B, Levasseur R, Zambuto L, Chen Y, Karsenty G, et al. (2005)
Osteopetrosis-like phenotype in latent TGF-beta binding protein 3 deficient
mice. Bone 37(1):25–31.
31. Nistala H, Lee-Arteaga S, Smaldone S, Siciliano G, Carta L, et al. (2010)
Fibrillin-1 and -2 differentially modulate endogenous TGF-beta and BMP
bioavailability during bone formation. J Cell Biol 190(6):1107–21.
32. Javed A, Bae JS, Afzal F, Gutierrez S, Pratap J, et al. (2008) Structural coupling
of Smad and Runx2 for execution of the BMP2 osteogenic signal. J Biol Chem
283(13):8412–22.
33. Ehnert S, Zhao J, Pscherer S, Freude T, Dooley S, et al. (2012) Transforming
growth factor beta1 inhibits bone morphogenic protein (BMP)-2 and BMP-7
signaling via upregulation of Ski-related novel protein N (SnoN): possible
mechanism for the failure of BMP therapy? BMC Med 10:101.
34. Matsumoto Y, Otsuka F, Hino J, Miyoshi T, Takano M, et al. (2012) Bone
morphogenetic protein-3b (BMP-3b) inhibits osteoblast differentiation via
Smad2/3 pathway by counteracting Smad1/5/8 signaling. Mol Cell Endocrinol
350(1):78–86.

11

May 2014 | Volume 9 | Issue 5 | e98388

